Matthias Klinger
Overview
Explore the profile of Matthias Klinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
3159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sadat N, Lojenburg J, Scharfschwerdt M, Klinger M, Fujita B, Ensminger S
Health Sci Rep
. 2024 Aug;
7(8):e2304.
PMID: 39166121
Background And Aims: The durability of surgical aortic valve bioprostheses (SAV) is limited by the calcification of the leaflets, which results in degeneration. In clinical routine, there seems to be...
2.
Boddu V, Zamzow P, Kramer M, Merseburger A, Gorantla S, Klinger M, et al.
Cell Commun Signal
. 2024 Feb;
22(1):129.
PMID: 38360687
Background: Extracellular vesicles (EVs), including microvesicles, hold promise for the management of bladder urothelial carcinoma (BLCA), particularly because of their utility in identifying therapeutic targets and their diagnostic potential using...
3.
Locatelli F, Markovic A, Klinger M, Zeng T, Zugmaier G
Pediatr Blood Cancer
. 2023 May;
:e30435.
PMID: 37246348
We analyzed changes in laboratory parameters, including blood counts, liver enzymes, inflammation and coagulation markers, and cytokines, from 70 blinatumomab-treated pediatric patients (NCT01471782). Overall, trends were consistent in responders and...
4.
Radine U, Bumiller-Bini Hoch V, Boldt A, Zillikens D, Ludwig R, Hammers C, et al.
Front Med (Lausanne)
. 2022 Dec;
9:997387.
PMID: 36452895
Pemphigus is a chronic autoimmune skin blistering disease, characterized by acantholysis and by the production of autoantibodies directed against the structural desmosomal proteins desmoglein 1 (DSG1) and/or DSG3. Model systems...
5.
Mejstrikova E, Klinger M, Markovic A, Zugmaier G, Locatelli F
Pediatr Blood Cancer
. 2021 Sep;
68(12):e29323.
PMID: 34519430
Blinatumomab is a BiTE (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL); however, a subset...
6.
Noguera P, Klinger M, Orun H, Grunow B, Del-Pozo J
J Fish Dis
. 2021 Aug;
44(12):2031-2041.
PMID: 34424537
Salmon pancreas disease virus (SPDV) has been affecting the salmon farming industry for over 30 years, but despite the substantial amount of studies, there are still a number of recognized...
7.
Nagele V, Zugmaier G, Goebeler M, Viardot A, Bargou R, Kufer P, et al.
Exp Hematol
. 2021 Jul;
100:32-36.
PMID: 34228983
Blinatumomab is a first-in-class immunotherapy based on the bispecific T-cell engager (BiTE®) immune-oncology platform, which redirects CD3 T cells to kill CD19 target cells. The objective of this analysis was...
8.
Shima K, Kaufhold I, Eder T, Kading N, Schmidt N, Ogunsulire I, et al.
mBio
. 2021 Mar;
12(2).
PMID: 33785629
Infection with the obligate intracellular bacterium is the most common bacterial sexually transmitted disease worldwide. Since no vaccine is available to date, antimicrobial therapy is the only alternative in infection....
9.
Goldstein R, Goyos A, Li C, Deegen P, Bogner P, Sternjak A, et al.
Blood Adv
. 2020 Sep;
4(17):4180-4194.
PMID: 32886754
Multiple myeloma (MM) is a hematologic malignancy that is characterized by the accumulation of abnormal plasma cells (PCs) in the bone marrow (BM). Patient outcome may be improved with BiTE...
10.
Shima K, Weber M, Schnee C, Sachse K, Kading N, Klinger M, et al.
mSphere
. 2020 Aug;
5(4).
PMID: 32848009
The obligate intracellular bacterium is a known avian pathogen causing psittacosis in birds and is capable of zoonotic transmission. In human pulmonary infections, can cause pneumonia associated with significant mortality...